CAR-T

| CRISPR Medicine | This is an overview of articles on CAR-T

Gene-Editing IND and Pre-clinical Update

Dec. 23, 2020

Update on Allogene Therapeutics off-the-shelf CAR-T cancer therapies. This week’s gene-editing update looks at an investigational new drug (IND)...

Gene-Editing Clinical Trial Update

Dec. 16, 2020

In this week’s clinical update, we look at three clinical-stage CRISPR-engineered cell therapies that are under development for the treatment of acute...

Multiple Myeloma, MM, (ALLO-605)
Sponsors:
Allogene Therapeutics, Inc.

Pre-clinical

Phase I

Phase II

Phase III

Renal Cell Carcinoma, RCC, (ALLO-316)
Sponsors:
Allogene Therapeutics, Inc.

Pre-clinical

Phase I

Phase II

Phase III

Pre-clinical Development CRISPR Update

Dec. 3, 2020

Last week, we bought you our first IND update for a selection of gene-editing therapies currently under development for blood disorders. This week, we...

B-Cell Malignancies, NHL, (NCT04629729)
Sponsors:
Fate Therapeutics

Pre-clinical

Phase I

Phase II

Phase III

B Cell Non-Hodgkin Lymphoma, NHL, (NCT04637763)
Sponsors:
Caribou Biosciences, Inc.

Pre-clinical

Phase I

Phase II

Phase III

B- cell Acute Lymphoblastic Leukaemia, ALL, (NCT03666000)
Sponsors:
Precision BioSciences, Inc.

Pre-clinical

Phase I

Phase II

Phase III